SCHEMBL5033264

SCHEMBL5033264

CN1C(=O)[N]C(=O)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.52
CES1 P23141 1/20 0.52
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GABRA1 P14867 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
CCKBR P32239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7558704 0.76 CES1 (0.34) TTRCES1ALDH1A1HPGDKDM4E
SCHEMBL14916405 0.76 MEN1 (0.47) CES1ALDH1A1HPGDMAPTKDM4E
SCHEMBL2354261 0.75 TTR (0.41) TTRCES1ALDH1A1HPGDMAPT
SCHEMBL11438012 0.72 CES1 (0.47) TTRCES1ALDH1A1HPGDMAPT
SCHEMBL19888 0.72 MEN1 (0.50) CES1ALDH1A1MAPTKDM4ELMNA
SCHEMBL16127516 0.72 TTR (0.75) TTRCES1ALDH1A1HPGDMAPT
SCHEMBL6404457 0.71 MEN1 (0.50) CES1ALDH1A1MAPTKDM4ELMNA
SCHEMBL25635330 0.70 TTR (0.58) TTRCES1ALDH1A1HPGDMAPT
SCHEMBL12059596 0.68 TTR (0.69) TTRCES1ALDH1A1HPGDMAPT
SCHEMBL13039623 0.68 TTR (0.69) TTRCES1ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP claimed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 US claimed
US-5801181-A Amino alcohol substituted cyclic compounds CELL THERAPEUTICS, INC. (US) 1998-09-01 US claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP disclosed
US-6410580-B1 ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES NOVARTIS AG (CH) 2002-06-25 US disclosed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 US disclosed